Evidence map›Paper›PMID 29864037›Full record

Trial reportInternational clinical psychopharmacology2018

Effects of anxiety on suicidal ideation: exploratory analysis of a paroxetine versus bupropion randomized trial.

Michelle S Parris, Julia E Marver, Sadia R Chaudhury, Steven P Ellis, Allison V Metts, John G Keilp, Ainsley K Burke, Maria A Oquendo, Joseph J Mann, Michael F Grunebaum

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International clinical psychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Pharmacological interventions for self-harm in adults.The Cochrane database of systematic reviews · 2021
    Pooled it
  3. Trial
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Michelle S ParrisDepartment of Psychiatry, Columbia University, and New York State Psychiatric Institute, New York, New York.
Julia E MarverDepartment of Psychiatry, Columbia University, and New York State Psychiatric Institute, New York, New York.
Sadia R ChaudhuryDepartment of Psychiatry, Columbia University, and New York State Psychiatric Institute, New York, New York.
Steven P EllisDepartment of Psychiatry, Columbia University, and New York State Psychiatric Institute, New York, New York.
Allison V MettsDepartment of Psychiatry, Columbia University, and New York State Psychiatric Institute, New York, New York.
John G KeilpDepartment of Psychiatry, Columbia University, and New York State Psychiatric Institute, New York, New York.
Ainsley K BurkeDepartment of Psychiatry, Columbia University, and New York State Psychiatric Institute, New York, New York.
Maria A OquendoDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Joseph J MannDepartment of Psychiatry, Columbia University, and New York State Psychiatric Institute, New York, New York.
Michael F GrunebaumDepartment of Psychiatry, Columbia University, and New York State Psychiatric Institute, New York, New York.
New York Psychoanalytic Society and Institute · USNew York State Psychiatric InstituteColumbia University · USUniversity of Pennsylvania · US

Funding

THE NEUROBIOLOGY OF SUICIDAL BEHAVIORP50MH062185 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI MANN, JOSEPH JOHN · 2000 to 2009
$21.7M
Paroxetine/Bupropion in Suicide Attempters/Ideators with Major DepressionK23MH076049 · NIMH · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GRUNEBAUM, MICHAEL F · 2006 to 2010
$884k
NIMH NIH HHS K23 MH076049NIMH NIH HHS P50 MH062185
6 · The paper itself

Abstract

It is unclear whether anxiety increases or decreases suicidal risk. This may contribute to the lack of guidance on which antidepressant medications are best for suicidal depressed patients who present with high anxiety. This study explored whether anxiety predicts suicidal ideation in depressed individuals treated with paroxetine or bupropion. An 8-week double-blind trial comparing controlled-release paroxetine (N=36) versus extended-release bupropion (N=38) for effect on suicidal ideation and behavior in depressed patients with suicidal ideation, past attempt, or both found an advantage for paroxetine, but anxiety effects were not investigated. This secondary analysis explored the relationship, measured at baseline and weekly, of anxiety with suicidal ideation. Anxiety severity measured weekly correlated with suicidal ideation severity irrespective of treatment (P=0.012). Patients with high baseline anxiety showed a trend toward faster reduction of suicidal ideation with paroxetine compared with bupropion treatment (standard P=0.047; bootstrap P=0.077). The latter finding, if confirmed in larger samples, could enhance choice of antidepressant medication for suicidal, depressed patients presenting with high levels of anxiety.

Indexed as

Suicidal IdeationAdultAntidepressive Agents, Second-GenerationAnxietyBupropionDelayed-Action PreparationsDouble-Blind MethodFemaleHumansMajor Depressive DisorderMaleMiddle AgedParoxetinePsychiatric Status Rating ScalesSuicide, AttemptedTreatment OutcomeAntidepressive Agents, Second-GenerationBupropionDelayed-Action PreparationsParoxetine

Identifiers

PMID29864037
PMCPMC6066420
OpenAlexW2807038265

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.